| 1 |
35261903 | Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. | 2022 Jan |
1 |
| 2 |
35437784 | Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitors. | 2022 Apr 18 |
2 |
| 3 |
32052681 | Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. | 2021 |
3 |
| 4 |
33436042 | The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. | 2021 Jan 12 |
2 |
| 5 |
33916610 | Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. | 2021 Apr 4 |
1 |
| 6 |
33922992 | Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma. | 2021 Apr 25 |
3 |
| 7 |
34584898 | Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. | 2021 |
1 |
| 8 |
34596810 | Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways. | 2021 Nov |
4 |
| 9 |
34940128 | Effect of Regorafenib on P2X7 Receptor Expression and Different Oncogenic Signaling Pathways in a Human Breast Cancer Cell Line: A Potential of New Insight of the Antitumor Effects of Regorafenib. | 2021 Dec 9 |
2 |
| 10 |
31608707 | The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. | 2020 Jan |
1 |
| 11 |
31195212 | Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. | 2019 Jul |
1 |
| 12 |
31238539 | Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. | 2019 Jun 24 |
2 |
| 13 |
31856912 | Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. | 2019 Dec 19 |
1 |
| 14 |
32720931 | The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community Physician. | 2019 Aug |
1 |
| 15 |
29888133 | Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma. | 2018 |
3 |
| 16 |
30378405 | A man in his 50s with neurological symptoms during cancer treatment. | 2018 Oct 30 |
4 |
| 17 |
28422758 | First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. | 2017 Apr 20 |
2 |
| 18 |
28954993 | Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor. | 2017 |
1 |
| 19 |
29061771 | A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer. | 2017 Nov |
1 |
| 20 |
26832420 | [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. | 2016 Mar |
1 |
| 21 |
27117754 | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. | 2016 Apr 27 |
3 |
| 22 |
27166185 | Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. | 2016 Jun 7 |
2 |
| 23 |
27364975 | Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. | 2016 Jul 1 |
3 |
| 24 |
26045027 | Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. | 2015 |
1 |
| 25 |
26327919 | Management of regorafenib-related toxicities: a review. | 2015 Sep |
1 |
| 26 |
26399347 | The malignant progression effects of regorafenib in human colon cancer cells. | 2015 |
1 |
| 27 |
26451083 | Clinical utility of ramucirumab in advanced gastric cancer. | 2015 |
2 |
| 28 |
24623990 | Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. | 2014 |
1 |
| 29 |
24772337 | Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. | 2014 Apr |
1 |
| 30 |
25326159 | Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. | 2014 Nov |
1 |
| 31 |
23334510 | Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma. | 2013 Apr |
4 |
| 32 |
24047557 | [Regorafenib approved in Metastatic Colorectal cancer]. | 2013 Oct |
1 |